News about "Shilpa Medicare"

Shilpa Medicare Signs Long-Term Manufacturing and Development Pact with NXI Therapeutics AG

Shilpa Medicare and NXI Therapeutics AG have entered into a long-term agreement to support development and commercial manufacturing of immunomodulatory therapies, expanding Shilpa’s global CDMO footprint in high-growth biologics and specialty therapeutics.

Shilpa Medicare | 14/05/2026 | By News Bureau

Shilpa Medicare Targets US Approval for Oeris After Successful Phase Three Trial

Shilpa Medicare seeks licensing partners for extended-release ondansetron injection to treat chemotherapy-induced nausea and vomiting.

Shilpa Medicare | 09/01/2026 | By News Bureau |  176

Koanna International and PPI to Form JV to Build New Pharma Manufacturing Facility in Saudi Arabia

Pharma Pharmaceutical Industries & Biological Products (PPI) of Saudi Arabia and Koanna International FZ LLC, a wholly-owned subsidiary of Shilpa Medicare, have signed a definitive agreement to establish a joint venture to set up a pharma manufacturing facility in Saudi Arabia.

Shilpa Medicare | 28/08/2025 | By Mrinmoy Dey |  563

Shilpa Medicare Secures CDSCO Approval for NorUDCA Tablets in NAFLD Treatment

Shilpa Medicare Ltd has received approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).

Shilpa Medicare | 16/08/2025 | By Dineshwori |  591

Alveolus Bio Secures Strategic Investment from Shilpa Medicare

Alveolus Bio has announced a strategic financing round led by Shilpa Medicare, which will also serve as its exclusive global development and manufacturing partner to accelerate clinical advancement of its inhaled biotherapeutics for respiratory diseases.

Shilpa Medicare | 04/08/2025 | By Mrinmoy Dey |  185

Amneal Launches BORUZU for Multiple Myeloma and Mantle Cell Lymphoma

BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma.

Shilpa Medicare | 07/04/2025 | By Aishwarya |  283

Shilpa Medicare Gets SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets

Shilpa Medicare Ltd. had earlier completed phase-3 clinical studies of this novel product SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets.

Shilpa Medicare | 12/03/2025 | By Aishwarya |  747

Shilpa Medicare Launches ORAAL for the Treatment of Oral Mucositis

ORAAL, a substantial advancement in Oral Mucositis management, has been accepted and approved by the Indian Dental Association.

Shilpa Medicare | 16/10/2023 | By Manvi |  1242

Shilpa Medicare gets two minor observations from US FDA at Hyderabad facility

The observations were noticed at Unit VII, Analytical Services Division

Shilpa Medicare | 13/03/2023 | By Sudeep Soparkar |  1474

Shilpa Medicare registers Bengaluru facility with Ministry of Health, UAE

The facility is involved in the manufacturing and testing of specialized dosage forms eg. Orodispersible Films and Transdermal systems

Shilpa Medicare | 20/02/2023 | By Sudeep Soparkar |  1252